Sign inJoin waitlistJoin the waitlist

Ruobing Xue

Program Director · University of Missouri-Columbia School of Medicine

Credentials: · · · · · ·

History

University of Missouri-Columbia School of Medicine
Present
University of Missouri-Columbia School of Medicine · University of Missouri School of Medicine
Present

Hematology and Medical Oncology
University of Louisville Brown Cancer Center
2022–2025
Internal Medicine
University of Missouri-Columbia School of Medicine
2019–2022
Sun Yat-sen University of Medical Sciences
2012–2016

Research

Increasing cure rates of solid tumors by immune checkpoint inhibitors
Review · Experimental Hematology and Oncology · 2023 · Co-first of 8 authors · 101 citations
Mast Cell Tryptase Contributes to Pancreatic Cancer Growth through Promoting Angiogenesis via Activation of Angiopoietin-1
International Journal of Molecular Sciences · 2016 · 44 citations
Sex-Specific Trends in Temporary Mechanical Circulatory Support Use as Bridge to Orthotopic Heart Transplant
JACC Advances · 2026

Adam DeVore
1 paper
Adam Rojan
1 paper
Amar Doshi
1 paper
CP
Chong-Xian Pan
1 paper
Heather Rose
1 paper
Hizra Farrukh
1 paper
Joseph Mishkin
1 paper
Lauren Harmon
1 paper · 1 as a resident
Lei Zheng
1 paper
Nicole Cyrille-Superville
1 paper
Onyedika Ilonze
1 paper
Priyesh Patel
1 paper

Clinical trials

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Site PI · Recruiting
Alliance for Clinical Trials in Oncology
2022–2027
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Site PI · Recruiting · Phase 2, Phase 3
NRG Oncology
2022–2030
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Sub-investigator · Recruiting
Bo Lu
2024–2030